A first-in-class triple-agonist medication on the cutting edge of metabolic care — targeting three pathways (GLP-1, GIP, and glucagon) for appetite control and metabolism. Arriving soon; join the waitlist.
Retatrutide is an investigational triple-agonist medication that activates three metabolic receptors — GLP-1, GIP, and glucagon — to reduce appetite and support metabolism, building on the mechanisms of semaglutide and tirzepatide. Physician-guided retatrutide programs are coming soon to Forever Glow in Leander, TX. Join the waitlist to be notified the moment booking opens.
We are preparing to add retatrutide as the newest option in our physician-guided weight-loss programs. Here is what to look forward to.
Targets GLP-1, GIP, and glucagon receptors — a step beyond today’s dual-action options.
Designed to curb appetite while supporting how the body uses energy.
Will be offered only within a supervised program with labs, dosing, and check-ins.
Paired with nutrition and lifestyle support — never a medication in isolation.
Join the waitlist and we will reach out the moment retatrutide programs are available. You will get first access to booking and any launch details — and as always, every program begins with a medical review and labs to confirm it is right and safe for you.